The first RNA interference (RNAi) therapy was approved in 2018, after 20 years in development. What can we expect to see in the RNAi field in the future? After two…
The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. …
AstraZeneca is recruiting RNAi specialist Silence Therapeutics to develop treatments for cardiovascular, renal, metabolic, and respiratory diseases. RNA interference, or RNAi, is a relatively new field of medicine in which…
The UK-based biotech Silence Therapeutics has signed a deal worth up to €553M ($693M) with the UK pharma company Mallinckrodt to develop RNA interference (RNAi) therapies for autoimmune diseases. Mallinckrodt…
Silence Therapeutics and Alnylam have reached a settlement that puts an end to a legal dispute between them resulting in Silence receiving some royalties on Onpattro, the first RNA interference…
Although biotech may seem like an industry that has only just gotten started, it was already up and running before the turn of the century. We took a look back…
You’ve certainly heard about antibodies, peptides and even DNA as therapeutics, but what about RNA? In this review, we paint an overview of what’s up in a young field that…
Silence Therapeutics just announced preclinical data for a novel CRISPR therapy targeted to the liver using its RNAi delivery expertise. How does it plan to find a space in this challenging and…